Projects per year
Organization profile
Organisation profile
宗旨：
促進本校生技醫藥商品化發展，提供一校三院同仁醫藥品研發服務，以開發具有創新性與前瞻性之生技醫藥產品開發為宗旨。
背景：
生技醫藥為我國重要產業，建立藥品及醫材開發的關鍵價值鏈平台是校園研究成果產業化最大的助力。為有效統整及加速本校之新藥及醫材研發能量，規劃成立臺北醫學大學生技醫藥商品化中心(TMU Biomedical Commercialization Center)，藉由商品化中心跨院系所專業團隊間的整合運作，提供一校三院同仁生技藥品臨床前到IND申請之臨床前研究(pre-clinical study)諮詢與服務。此外，透過北醫事業發展處協助醫藥品商品化開發策略，包含藥物市場定位分析，法規、專利檢索和諮詢服務，技術轉移或尋求業界承接產學合作案，及衍生新創事業體之相關規劃。
目的：
整合新藥開發及醫療器材從臨床前研究到IND/IDE所需之技術發展平台(Research Development)，提供校內外單位委託合作或共同開發之服務。
搭配事業發展處之資源協助擬定生技醫藥品商業化發展策略(Business Development)、專利布局及商業化輔導，以加速產出具有創新性與前瞻性的生技醫藥品。
初期以藥品的商業化平台為目標：規劃由藥物設計/合成與篩選、藥理活性、藥物動力學、藥物代謝、藥效、毒理、小試量產、製劑開發等提供平台服務。
Fingerprint The fingerprint is based on mining the text of the scientific documents related to the associated persons. Based on that an index of weighted terms is created, which defines the key subjects of research unit
Histone Deacetylase Inhibitors
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Cells
Chemical Compounds
Histone Deacetylases
Medicine & Life Sciences
Apoptosis
Medicine & Life Sciences
Mucocutaneous Lymph Node Syndrome
Medicine & Life Sciences
Tubulin
Medicine & Life Sciences
Tubulin Modulators
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Profiles
Wei-Chiao Chang
- Department of Clinical Pharmacy
- Master Program for Clinical Pharmacogenomics and Pharmacoproteomics
- Ph.D Program in Biotechnology Research and Development
- TMU Research Center of Cancer Translational Medicine
- TMU Biomedical Commercialization Center
Person: Researcher
Projects 2010 2019
運用有機金屬偶聯反應於抗癌試劑合(2/2)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
醇溶玉米蛋白/酪蛋白鈉奈米粒子之複合水凝膠於小干擾RNA基因局部及持續釋放傳遞之製備與特性之研究(3/3)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
探討苯乙醇苷衍生物對於藍光與氧化性物質視黃醛引起視網膜退化之藥理作用機制與視網膜病變之保護療效評估(2/3)
8/1/18 → 7/31/19
Project: A - Government Institution › b - Ministry of Science and Technology
Research Output 1996 2019
1
Citation
(Scopus)
1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., Jan 15 2019, In : European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.Research output: Contribution to journal › Article
Benzamides
Histone Deacetylases
Tubulin
Heterografts
Inhibitory Concentration 50
Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo
Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., Jun 1 2019, In : Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.Research output: Contribution to journal › Article
Triple Negative Breast Neoplasms
Histone Deacetylase Inhibitors
Breast Neoplasms
Histone Deacetylases
Acetylation
Association of endothelin genetic variants and hospitalized infection complications in end-stage renal disease (ESRD) patients
Kao, C. C., Cheng, S. Y., Wang, Y. J., Chien, S. C., Hsu, Y. W., Wu, M. Y., Lu, H. F., Nam, S., Sun, T., Wu, M. S. & Chang, W. C., Jun 5 2019, In : BMC Nephrology. 20, 1, 203.Research output: Contribution to journal › Article
Open Access
Endothelins
Chronic Kidney Failure
Bacteremia
Infection
Single Nucleotide Polymorphism
Press / Media
Hsu Felicia of Hotung Investment in second quartile of Mid Cap CFO Scorecard for past quarter
6/19/19
1 item of media coverage
Press/Media: Press / Media